Régions déterminant la complémentarité : Questions médicales fréquentes
Nom anglais: Complementarity Determining Regions
Descriptor UI:D022801
Tree Number:G02.111.570.060.425.160
Termes MeSH sélectionnés :
Prostatic Neoplasms
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Régions déterminant la complémentarité : Questions médicales les plus fréquentes",
"headline": "Régions déterminant la complémentarité : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Régions déterminant la complémentarité : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-06",
"dateModified": "2025-03-03",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Régions déterminant la complémentarité"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Région variable d'immunoglobuline",
"url": "https://questionsmedicales.fr/mesh/D007135",
"about": {
"@type": "MedicalCondition",
"name": "Région variable d'immunoglobuline",
"code": {
"@type": "MedicalCode",
"code": "D007135",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G02.111.570.060.425"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Régions déterminant la complémentarité",
"alternateName": "Complementarity Determining Regions",
"code": {
"@type": "MedicalCode",
"code": "D022801",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Boris I Chobrutskiy",
"url": "https://questionsmedicales.fr/author/Boris%20I%20Chobrutskiy",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine, Oregon Health and Science University Hospital, Portland, Oregon, USA."
}
},
{
"@type": "Person",
"name": "George Blanck",
"url": "https://questionsmedicales.fr/author/George%20Blanck",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA."
}
},
{
"@type": "Person",
"name": "Elena S Klimtchuk",
"url": "https://questionsmedicales.fr/author/Elena%20S%20Klimtchuk",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Daniele Peterle",
"url": "https://questionsmedicales.fr/author/Daniele%20Peterle",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Lawreen H Connors",
"url": "https://questionsmedicales.fr/author/Lawreen%20H%20Connors",
"affiliation": {
"@type": "Organization",
"name": ""
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Presence of HPV in prostate tissue from patients submitted to prostate biopsy.",
"datePublished": "2023-01-13",
"url": "https://questionsmedicales.fr/article/36651430",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1590/acb371205"
}
},
{
"@type": "ScholarlyArticle",
"name": "Total Prostate Specific Antigen in Prostate Cancer Screening in Hyperglycemic Individuals.",
"datePublished": "2022-09-24",
"url": "https://questionsmedicales.fr/article/36253300",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clgc.2022.09.007"
}
},
{
"@type": "ScholarlyArticle",
"name": "The mendelian randomized study revealed the association of prostatitis with prostate cancer risk.",
"datePublished": "2024-10-20",
"url": "https://questionsmedicales.fr/article/39428439",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-76355-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "Automatic detection of prostate cancer grades and chronic prostatitis in biparametric MRI.",
"datePublished": "2023-05-26",
"url": "https://questionsmedicales.fr/article/37271051",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cmpb.2023.107624"
}
},
{
"@type": "ScholarlyArticle",
"name": "Is systematic prostate biopsy an overkill in metastatic prostate carcinoma ? A prospective validation.",
"datePublished": "2023-03-14",
"url": "https://questionsmedicales.fr/article/36917412",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11255-023-03531-2"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes chimiques",
"item": "https://questionsmedicales.fr/mesh/D055598"
},
{
"@type": "ListItem",
"position": 3,
"name": "Phénomènes biochimiques",
"item": "https://questionsmedicales.fr/mesh/D001669"
},
{
"@type": "ListItem",
"position": 4,
"name": "Région variable d'immunoglobuline",
"item": "https://questionsmedicales.fr/mesh/D007135"
},
{
"@type": "ListItem",
"position": 5,
"name": "Régions déterminant la complémentarité",
"item": "https://questionsmedicales.fr/mesh/D022801"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Régions déterminant la complémentarité - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Régions déterminant la complémentarité",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-14",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Régions déterminant la complémentarité",
"description": "Comment identifier les CDR dans un anticorps ?\nQuels tests révèlent la présence de CDR ?\nLes CDR peuvent-ils être visualisés ?\nQuel rôle joue la bioinformatique dans l'étude des CDR ?\nLes CDR sont-ils spécifiques à chaque anticorps ?",
"url": "https://questionsmedicales.fr/mesh/D022801?mesh_terms=Prostatic+Neoplasms&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Régions déterminant la complémentarité",
"description": "Quels symptômes indiquent une réponse immunitaire anormale ?\nLes CDR affectent-ils les symptômes d'infections ?\nComment les CDR influencent-ils les maladies allergiques ?\nLes CDR sont-ils liés à des symptômes de maladies auto-immunes ?\nPeut-on prédire des symptômes grâce aux CDR ?",
"url": "https://questionsmedicales.fr/mesh/D022801?mesh_terms=Prostatic+Neoplasms&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Régions déterminant la complémentarité",
"description": "Comment prévenir les maladies liées aux CDR ?\nLes CDR peuvent-ils être ciblés pour la prévention ?\nQuel rôle joue l'alimentation dans la prévention des maladies liées aux CDR ?\nLes tests génétiques aident-ils à prévenir les maladies liées aux CDR ?\nComment le mode de vie influence-t-il la prévention des maladies ?",
"url": "https://questionsmedicales.fr/mesh/D022801?mesh_terms=Prostatic+Neoplasms&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Régions déterminant la complémentarité",
"description": "Comment les CDR sont-ils utilisés en thérapie ?\nLes traitements ciblant les CDR sont-ils efficaces ?\nQuels types de médicaments ciblent les CDR ?\nLes CDR peuvent-ils être modifiés pour améliorer les traitements ?\nQuels sont les effets secondaires des traitements ciblant les CDR ?",
"url": "https://questionsmedicales.fr/mesh/D022801?mesh_terms=Prostatic+Neoplasms&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Régions déterminant la complémentarité",
"description": "Quelles complications peuvent survenir avec des CDR défectueux ?\nLes CDR sont-ils impliqués dans des complications infectieuses ?\nComment les CDR affectent-ils les traitements anticancéreux ?\nLes complications liées aux CDR peuvent-elles être traitées ?\nQuels sont les risques de complications lors de thérapies ciblant les CDR ?",
"url": "https://questionsmedicales.fr/mesh/D022801?mesh_terms=Prostatic+Neoplasms&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Régions déterminant la complémentarité",
"description": "Quels facteurs augmentent le risque de maladies liées aux CDR ?\nL'âge influence-t-il le risque lié aux CDR ?\nLe stress a-t-il un impact sur les CDR ?\nLes infections antérieures influencent-elles les CDR ?\nComment le mode de vie affecte-t-il les CDR ?",
"url": "https://questionsmedicales.fr/mesh/D022801?mesh_terms=Prostatic+Neoplasms&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les CDR dans un anticorps ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les CDR sont identifiés par séquençage et analyse des structures d'anticorps."
}
},
{
"@type": "Question",
"name": "Quels tests révèlent la présence de CDR ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests d'affinité et de liaison aux antigènes sont utilisés pour détecter les CDR."
}
},
{
"@type": "Question",
"name": "Les CDR peuvent-ils être visualisés ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, par des techniques comme la cristallographie aux rayons X ou la RMN."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la bioinformatique dans l'étude des CDR ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "La bioinformatique aide à prédire et modéliser les CDR à partir de séquences d'anticorps."
}
},
{
"@type": "Question",
"name": "Les CDR sont-ils spécifiques à chaque anticorps ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, chaque anticorps a des CDR uniques qui déterminent sa spécificité."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une réponse immunitaire anormale ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des allergies ou des maladies auto-immunes peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les CDR affectent-ils les symptômes d'infections ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des CDR efficaces peuvent réduire la gravité des symptômes d'infections."
}
},
{
"@type": "Question",
"name": "Comment les CDR influencent-ils les maladies allergiques ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des CDR spécifiques peuvent reconnaître des allergènes, entraînant des réactions."
}
},
{
"@type": "Question",
"name": "Les CDR sont-ils liés à des symptômes de maladies auto-immunes ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des CDR mal régulés peuvent cibler des tissus sains, provoquant des symptômes."
}
},
{
"@type": "Question",
"name": "Peut-on prédire des symptômes grâce aux CDR ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études sur les CDR peuvent aider à prédire la réponse immunitaire et les symptômes."
}
},
{
"@type": "Question",
"name": "Comment prévenir les maladies liées aux CDR ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vaccination et l'éducation sur les allergies peuvent aider à prévenir ces maladies."
}
},
{
"@type": "Question",
"name": "Les CDR peuvent-ils être ciblés pour la prévention ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des stratégies de vaccination ciblant les CDR peuvent prévenir certaines infections."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'alimentation dans la prévention des maladies liées aux CDR ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut renforcer le système immunitaire et prévenir les maladies."
}
},
{
"@type": "Question",
"name": "Les tests génétiques aident-ils à prévenir les maladies liées aux CDR ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier les risques et guider la prévention."
}
},
{
"@type": "Question",
"name": "Comment le mode de vie influence-t-il la prévention des maladies ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant exercice et gestion du stress, aide à prévenir les maladies."
}
},
{
"@type": "Question",
"name": "Comment les CDR sont-ils utilisés en thérapie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les CDR sont ciblés pour développer des anticorps thérapeutiques contre des maladies."
}
},
{
"@type": "Question",
"name": "Les traitements ciblant les CDR sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils montrent une efficacité dans le traitement de diverses maladies, y compris le cancer."
}
},
{
"@type": "Question",
"name": "Quels types de médicaments ciblent les CDR ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anticorps monoclonaux et des inhibiteurs de points de contrôle immunitaire ciblent les CDR."
}
},
{
"@type": "Question",
"name": "Les CDR peuvent-ils être modifiés pour améliorer les traitements ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la modification des CDR peut augmenter l'affinité et la spécificité des anticorps."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des traitements ciblant les CDR ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des réactions immunitaires indésirables et des allergies."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des CDR défectueux ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des CDR défectueux peuvent entraîner des maladies auto-immunes et des allergies."
}
},
{
"@type": "Question",
"name": "Les CDR sont-ils impliqués dans des complications infectieuses ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des CDR inefficaces peuvent aggraver les infections et retarder la guérison."
}
},
{
"@type": "Question",
"name": "Comment les CDR affectent-ils les traitements anticancéreux ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des CDR mal ciblés peuvent réduire l'efficacité des traitements anticancéreux."
}
},
{
"@type": "Question",
"name": "Les complications liées aux CDR peuvent-elles être traitées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements ciblés peuvent gérer les complications associées aux CDR."
}
},
{
"@type": "Question",
"name": "Quels sont les risques de complications lors de thérapies ciblant les CDR ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des réactions immunitaires indésirables et des effets secondaires graves."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de maladies liées aux CDR ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme la génétique, l'environnement et le mode de vie augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque lié aux CDR ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le vieillissement peut affecter la fonction des CDR et augmenter le risque de maladies."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur les CDR ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut altérer la réponse immunitaire et affecter les CDR."
}
},
{
"@type": "Question",
"name": "Les infections antérieures influencent-elles les CDR ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des infections passées peuvent modifier la structure et la fonction des CDR."
}
},
{
"@type": "Question",
"name": "Comment le mode de vie affecte-t-il les CDR ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut améliorer la fonction des CDR et réduire le risque de maladies."
}
}
]
}
]
}
Prostate cancer (PCa) is the second most frequent cancer among men in the Western population. Infections, such as the one caused by the human papillomavirus (HPV), have been shown to promote inflammat...
Prostate tissue fragments were collected by prostate biopsy and subjected to polymerase chain reaction with primers for the HPV L1 gene to identify the presence of the virus....
Among 162 patients, 10 (6.2%) had HPV and in 152 (93.8%) HPV was not identified in prostate biopsies. HPV was detected in 7/95 (7.4%) of patients with PCa, in 2/55 (3.6%) of patients without PCa, and ...
There were no significant levels of HPV L1 protein in prostate tissue. The findings suggest the absence of HPV oncogenic activity in the prostate tissue of patients with PCa....
In this study, it was aimed to investigate the reliability of total prostate-specific antigen (t-PSA) in prostate cancer screening in hyperglycemic (≥126 mg/dL) individuals....
This research was planned as a cross-sectional retrospective study. Three hundred eleven cases which underwent biopsy with the suspicion of prostate cancer in the hospital were included in the study. ...
It was determined that the t-PSA measurement was higher in the patient group with cancer (P < .001). It was determined that the median t-PSA levels of the intermediate and high cancer groups were high...
As a contribution to literature, we found that the t-PSA test lost its sensitivity in cases with plasma glucose levels above normal. Loss of sensitivity may result in underdiagnosis in prostate cancer...
In recent observational studies, a potential link between prostatitis and prostate cancer (PCa) has been hinted at, yet the causality remains ambiguous. In our endeavor to scrutinize the conceivable c...
With emerging evidence to improve prostate cancer (PCa) screening, multiparametric magnetic prostate imaging is becoming an essential noninvasive component of the diagnostic routine. Computer-aided di...
We collected 1647 fine-grained biopsy-confirmed findings, including Gleason scores and prostatitis, to form a training dataset. In our experimental framework for lesion detection, all models utilized ...
An optimal model configuration with fine class granularity (prostatitis included) and OHE has scored the lesion-wise partial Free-Response Receiver Operating Characteristic (FROC) area under the curve...
This paper examines several configurations for model training in the biparametric MRI setup and proposes optimal value ranges. It also shows that the fine-grained class configuration, including prosta...
To assess the efficacy of 2-core prostate biopsy in advanced prostate cancer patients. This included a retrospective analysis of 12-core prostate biopsies and a prospective validation that a reduced n...
The first phase analyzed retrospective data from 12-core prostate biopsies between January 2013 and 2018. In the second phase, from January 2018 to January 2022, in a prospective setting, patients wit...
In the retrospective analysis, the number of positive cores in metastatic disease was 12 in 93 (73.8%), 11 in 14 (11.1%), and 10 in 7 (5.6%) patients. Using probability analysis, 94% of patients with ...
A 2-core biopsy is adequate in almost all patients with metastatic prostate cancer with PSA > 75, and this avoids excess complications and morbidity associated with a systematic 12-core prostate biops...
Financial toxicity (FT) is a growing concern among cancer survivors that adversely affects the quality of life and survival. Individuals diagnosed with aggressive cancers are often at a greater risk o...
PCa patients enrolled in the North Carolina-Louisiana Prostate Cancer Project (PCaP) were recontacted for long-term follow-up. The prevalence of FT in the PCaP cohort was estimated. FT was estimated u...
More than one-third of PCa patients reported experiencing FT. PCa aggressiveness was significantly independently associated with high FT; high aggressive PCa at diagnosis had more than twice the risk ...
Aggressive PCa was associated with high FT. Future studies should collect more information about the characteristics of men with high FT and identify additional risk factors of FT....
Prostate-specific membrane antigen (PSMA) hybrid imaging is a promising new technique gaining importance in the field of prostate cancer (PCa) diagnosis and treatment planning. By combining PSMA radio...
Cribriform (CBFM) pattern on prostate biopsy has been implicated as a predictor for high-risk features, potentially leading to adverse outcomes after definitive treatment. This study aims to investiga...
Patients who underwent multiparametric magnetic resonance imaging (mpMRI), combined 12-core transrectal ultrasound (TRUS) guided systematic (SB) and MRI/US fusion-guided biopsy were retrospectively qu...
Between 2015 and 2022, a total of 131 consecutive patients with CBFM pattern on prostate biopsy and pre-biopsy mpMRI were included. Clinical feature analysis included 1572 systematic biopsy cores (114...
The extent of disease for CBFM-containing tumors is difficult to capture on mpMRI. When comparing MRI lesions of similar dimensions and PIRADS scores, CBFM-containing tumors appear to have larger canc...
Purpose: Determine the time-dependent magnitude of intrafraction prostate displacement and a cutoff for the tracking decision. Methods: Nine patients with localized prostate cancer were treated with u...
Apart from other risk factors, chronic inflammation is also associated with the onset of Prostate Cancer (PCa), wherein pathogen infection and tissue microbiome dysbiosis are known to play a major rol...